ABSTRACT
INTRODUCTION

51
The catecholamines epinephrine (EPI), dopamine (DA) and norepinephrine (NE) play a 52 key role in the regulation of blood pressure and sodium homeostasis through their action 53 on central and peripheral adrenergic and dopaminergic receptors. The known pathway 54 for the metabolism of these compounds involves uptake by neuronal and extraneuronal 55 tissues and degradation by the intracellular enzymes monoamine oxidases A and B
56
(MAO-A and B) and catechol-O-methyltransferase (COMT) (1, 21, 34) .
57
In kidney, the epithelial cells of proximal tubules (PT) are endowed with a high COMT and MAO might be involved in the regulation of renal DA output.
76
Renalase is a recently identified FAD/NADH-dependent amine oxidase mainly 77 expressed in kidney, which is secreted into blood where it was suggested to metabolize 78 catecholamines with preference for EPI as well as the catecholamine precursor L-DOPA 79 (7) (8) (37) (38) . When administered in vivo renalase acutely lowers blood pressure in a 80 dose-dependent manner and this was accompanied by decreased cardiac contractility 81 and heart rate without compensatory changes in peripheral vascular tone thus suggesting 82 that these hemodynamic effects may be accounted for by circulating catecholamines 83 degradation (3-4).
84
In addition to the kidney, renalase is also highly expressed in other organs, namely in 85 the heart, intestine, skeletal muscle, liver as well as in the peripheral and central nervous 86 system (CNS) (15) (16) 38 
MATERIALS AND METHODS
97
Metabolic studies
98
Renalase-deficient (KO) mice were generated as previously described (36). centrifuged for 60s at 16000g. Samples were immediately injected into a HPLC system 187 (Waters model 2690) with a photodiode array detector (Waters model 996).
188
As previously described (27), the chromatograms were analysed at 279 nm which carried out using NaIO 4 (2 mM). 
RESULTS
195
Baseline characteristics
196
The baseline characteristics of the KO mice, namely renal function and sodium balance,
197
did not differ from those of the corresponding WT controls ( In comparison with WT mice, the KO mice presented increased plasma levels of both
206
EPI and NE by ~254% and ~58%, respectively ( figure 1A ). In addition, the plasma 207 levels of DA and the deaminated metabolite DOPAC were significantly increased in
208
KO mice in comparison with WT group, by ~87% and ~22%, respectively (figure 1A).
209
In comparison with WT mice, the plasma levels of the DA precursor L-DOPA were also 210 increased in KO mice by ~41%, though the difference did not reach statistical 211 significance ( figure 1A ).
213
Renal dopamine system
214
In comparison with WT mice, the daily urinary excretion of EPI, NE and DA were 215 significantly increased in KO mice by ~42%, ~89% and ~99%, respectively (figure 1B).
216
This was accompanied in KO mice by a ~4-fold increase in the urinary DA/L-DOPA 217 ratios (figure 3A) in comparison to WT mice (2.41±0.54 vs 9.45±2.37, p<0.01) without 218 changes in renal AADC activity between the two groups (table 3) .
219
In comparison with WT mice, the KO mice presented a marked decrease in the daily 220 urinary levels of both DOPAC and HVA, by ~85% and ~229%, respectively (figure 221 1B). This was accompanied in KO mice by a significant decrease in renal MAO-B 222 activity without changes in renal MAO-A activity (table 3) . In addition, the KO mice 223 presented a marked increase in the daily urinary levels of 3-MT by ~123% (figure 1B) 224 which was associated with a significant increase in renal COMT activity (table 3) . The administration of RR to KO mice significantly reduced the plasma levels of EPI by 246 ~61%, and also decreased the plasma levels of NE by ~39%, though the difference did 247 not reach statistical significance ( figure 2A ). In addition, the administration of RR to 248 KO mice significantly reduced the plasma levels of both DA and L-DOPA by ~38% and 249 ~57%, respectively ( figure 2A) . Moreover, the administration of RR to KO mice 250 decreased the plasma levels of DOPAC by ~27%, though the difference did not reach 251 statistical significance ( figure 2A ).
252
The administration of RR to KO mice did not change the daily urinary excretion of 253 either EPI or NE (figure 2B) but significantly decreased the daily urinary excretion of
254
DA by ~36% ( figure 2B ). respectively, though the differences did not reach statistical significance ( figure 2B ).
262
Immunoblot analysis
263
The changes in the amino acid transporters that are potentially involved in the uptake of be the main mechanism underlying the increased renal DA output observed in renalase 291 KO mice.
292
As was previously reported (36), we found significant increases in circulating levels of of L-DOPA which was recently described as a good substrate for the enzyme (6).
345
The semiquantitative evaluation of the renal cortical expression of Na+-independent 346 amino acid transporter LAT1, involved in renal tubular uptake of L-DOPA also 347 reinforce the view that the increased renal DA activity in renalase KO mice appears to 348 result mainly from an enhanced availability/uptake of L-DOPA in renal PT cells.
349
Although, LAT1 has been previously described to have a very limited tissue distribution would account for decreased L-DOPA uptake, and diminished renal dopamine output.
359
In summary, the up-regulation of renal DA activity in renalase KO mice appears to 
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